Q-omics provides the consensus-scored ANXA10 profile across patient tissues and cancer cell-line models. ANXA10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ANXA10 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ANXA10 protein abundance shows 25,242 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, HNSC, and LSCC as cancer lineages where ANXA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANXA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANXA10 survival associations across molecular data types. ANXA10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANXA10 RNA expression–survival associations across cancer types. High ANXA10 expression shows unfavorable associations in LUAD, DLBC, HNSC and THYM, but favorable associations in LIHC and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ANXA10 RNA expression.
This table summarizes ANXA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANXA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANXA10 shows lower tumor expression in LIHC, CHOL and KICH and higher tumor expression in HNSC, LUAD and KIRC. The HNSC box plot shows higher ANXA10 RNA expression in tumor versus normal tissue (log2 FC = +0.826, t-test p < 0.001).
This table shows molecular features associated with ANXA10 in patient tissues and cancer cell lines. In patient samples, ANXA10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANXA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and STOMACH.
